GlassScriptPhysician profile
Elizabeth L Turner
NPI 1437177441
$11,517.64
in general payments reported to CMS, 2019-2025
36 companies · $1,699 in 2025
The $1,699 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,262 · 2020: $1,021 · 2021: $1,420 · 2022: $2,399 · 2023: $1,729 · 2024: $1,988 · 2025: $1,699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,178 · Education: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,178.23 |
| Education | $237.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,771.73 | 2019-2025 | Skyrizi, Rinvoq |
| Amgen INC. | $1,469.60 | 2019-2025 | Enbrel, Otezla, Evenity |
| Janssen Biotech, INC. | $1,254.47 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $986.03 | 2019-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $937.22 | 2019-2025 | Benlysta |
| Pfizer INC. | $899.24 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $627.96 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $488.93 | 2019-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $382.98 | 2021-2025 | Saphnelo |
| Lilly USA, LLC | $379.55 | 2019-2024 | Taltz |
| Aurinia Pharma U.S., INC. | $292.00 | 2021-2023 | Lupkynis |
| Radius Health, INC. | $287.55 | 2019-2025 | Tymlos |
| Mallinckrodt Hospital Products INC. | $220.10 | 2021-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $164.56 | 2023-2024 | Purified Cortrophin Gel |
| Sanofi-Aventis U.S. LLC | $159.04 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.63 | 2019-2024 | Cyltezo, Ofev |
| Alexion Pharmaceuticals, INC. | $125.37 | 2020-2024 | Ultomiris, Strensiq |
| Genentech USA, INC. | $118.87 | 2019-2025 | Actemra |
| Organon LLC | $118.82 | 2022-2025 | Hadlima, Renflexis |
| Genzyme Corporation | $87.88 | 2019-2025 | |
| Sandoz INC. | $84.39 | 2024-2025 | Hyrimoz |
| Sobi, INC | $79.73 | 2021-2023 | |
| Horizon Therapeutics Plc | $77.71 | 2020-2022 | |
| Scilex Pharmaceuticals INC. | $55.07 | 2024-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $47.32 | 2024 | Arcalyst |
| Ultragenyx Pharmaceutical INC. | $39.63 | 2021-2023 | |
| Fresenius Kabi USA, LLC | $36.80 | 2023-2025 | Idacio |
| Depuy Synthes Sales INC. | $30.72 | 2022 | |
| Hikma Pharmaceuticals USA | $30.58 | 2019-2023 | Mitigare |
| Celltrion USA INC. | $23.26 | 2023 | Yuflyma |
| Actelion Pharmaceuticals US, INC. | $23.20 | 2023 | Uptravi, Opsumit |
| Celgene Corporation | $22.92 | 2019 | |
| Kyowa Kirin, INC. | $19.40 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $17.94 | 2023 | Arcalyst |
| Almatica Pharma LLC | $17.40 | 2024 | Teriparatide |
| Merck Sharp & Dohme LLC | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.